← Back to Search

Multi-mineral Natural Product

Aquamin for Bad Breath

Phase 2
Recruiting
Led By James Varani
Research Sponsored by University of Michigan
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Self-reported halitosis
Periodontally stable
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 90 days (post-intervention)
Awards & highlights

Study Summary

This trial will test whether Aquamin, a natural product made from red marine algae, can help reduce halitosis (bad breath) over a 90 day period.

Who is the study for?
This trial is for people with self-reported bad breath who are periodontally stable and can consent to study rules. They must not eat, drink, smoke, or use mouthwash an hour before visits and agree not to scrape their tongue during the study. Women must test negative for pregnancy and use birth control.Check my eligibility
What is being tested?
The trial tests if Aquamin®, a natural multi-mineral supplement from red marine algae, reduces halitosis over 90 days. Participants will take Aquamin® and adhere to specific oral hygiene practices throughout the study.See study design
What are the potential side effects?
Potential side effects of Aquamin® aren't specified in this summary but considering it's a natural mineral product, they may be minimal compared to pharmaceuticals; however, participants should report any adverse reactions.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below
Select...
I believe I have bad breath.
Select...
My gums are healthy and do not have any major issues.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~90 days (post-intervention)
This trial's timeline: 3 weeks for screening, Varies for treatment, and 90 days (post-intervention) for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Halitosis Associated Life-quality Test (HALT) questionnaire (modified)

Trial Design

1Treatment groups
Experimental Treatment
Group I: Aquamin®Experimental Treatment1 Intervention

Research Highlights

Information in this section is not a recommendation. We encourage patients to speak with their healthcare team when evaluating any treatment decision.
Mechanism Of Action
Side Effect Profile
Prior Approvals
Other Research
Common treatments for bad breath include maintaining good oral hygiene, using antimicrobial mouthwashes, and dietary supplementation. Good oral hygiene practices, such as regular brushing and flossing, help remove food particles and plaque that harbor bacteria responsible for bad breath. Antimicrobial mouthwashes, like those containing chlorhexidine, reduce the bacterial load in the mouth, thereby decreasing the production of foul-smelling compounds. Dietary supplements, such as Aquamin® (a multi-mineral product from red marine algae), may improve oral health by providing essential minerals that strengthen teeth and gums, potentially reducing the bacterial biofilm and inflammation associated with halitosis. These treatments are crucial for bad breath patients as they address the underlying causes of halitosis, leading to improved oral health and fresher breath.

Find a Location

Who is running the clinical trial?

University of MichiganLead Sponsor
1,811 Previous Clinical Trials
6,384,791 Total Patients Enrolled
James VaraniPrincipal InvestigatorUniversity of Michigan
2 Previous Clinical Trials
70 Total Patients Enrolled
Muhammad N AslamStudy DirectorUniversity of Michigan
2 Previous Clinical Trials
70 Total Patients Enrolled

Media Library

Aquamin (Multi-mineral Natural Product) Clinical Trial Eligibility Overview. Trial Name: NCT05058638 — Phase 2
Bad Breath Research Study Groups: Aquamin®
Bad Breath Clinical Trial 2023: Aquamin Highlights & Side Effects. Trial Name: NCT05058638 — Phase 2
Aquamin (Multi-mineral Natural Product) 2023 Treatment Timeline for Medical Study. Trial Name: NCT05058638 — Phase 2
Bad Breath Patient Testimony for trial: Trial Name: NCT05058638 — Phase 2
~4 spots leftby Jul 2025